Form 4 for HRTX HERON THERAPEUTICS, INC. /DE/
Accepted 2022-05-04 00:00:00 ET · period of report 2022-05-03 · accession 0001209191-22-027232 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-04 | 2022-05-03 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | S - Sale | $4.76 | -1,504 | 10.9K | -12% | -$7,159 | |
| 2022-05-04 | 2022-04-29 | HRTX | MANHARD KIMBERLY | EVP, Drug Development, Dir | J - Other | $3.84 | +1,504 | 12.4K | +14% | +$5,775 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-03 | S | D | 1,504 | $4.76 | 10,872 | D | — | — | (F3) The range of sales prices received was $4.695 to $4.835. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. |
| 2 | Common | Common Stock | 2022-04-29 | J | A | 1,504 | $3.84 | 12,376 | D | — | — |